Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Irulecrapon Nov 22, 2010 12:10pm
427 Views
Post# 17739328

HOLDINGS SUMMARY

HOLDINGS SUMMARY
QEI.V : TSXV


HOLDINGS SUMMARY

Shareholders

Top Shareholders

Large Block Owners 9
Total Number of Shares Held 111.1M
% Change in Ownership 0%
% Shares Owned 52%
 
Monthly Rotation Number
of Shares
Value of
Change (MM)
% of Shrs.
Outstanding
Buyers 11/21/10 72,251,161 $11.00 58.9%
Sellers 11/21/10 7,361,792 $1.12 5.7%
 
Holdings chart
Institutions:
5 Holders
$13,541,343 Value
52.1% Owned of O/S
Mutual Funds:
6 Holders
$2,502,834 Value
9.8% Owned of O/S
Other Major Holders:
4 Holders
$1,243,120 Value
3.1% Owned of O/S
Institutions
5 Holders
Mutual Funds
6 Holders
Other Major Holders
4 Holders
 

SHAREHOLDERS CONCENTRATION

55.3%

Top Institutional Holders

Concentration of Current % Held
Top 10 Institutions: Ownership by top 10 institutions Top 20 Institutions: Ownership by top 20 institutions Top 50 Institutions: Ownership by top 50 institutions All: Ownership by all institutions
Low
Avg. Turnover Rating
Goodman & ...
31.9M
$4,508,937 +29% 15.9%
Moderate
Sprott Asset ...
26.6M
$3,797,503 +24% 13.2%
Low
Front Street ...
24.3M
$3,428,959 +22% 12.1%
Low
Rosseau Asset ...
11.5M
$2,100,510 +10% 5.7%
Moderate
Pinetree Capital ...
10.6M
$2,208,268 +10% 5.3%
Low
DiCapo (Pasquale)
5.3M
$1,097,785 +5% 2.6%
Low
Patricio (Richard)
505.0K
$72,188 0% 0.3%
Low
Szczuczko (Robert)
436.0K
$62,324 0% 0.2%
--
Austin (Stephen)
75.7K
$10,823 0% 0.0%
Low
Federated ...
0.0
0 0% 0.0%
Moderate

Top Mutual Fund Holders

Percentage of Outstanding Shares per Holdings Style
GARP 0.2%
Moderate
Avg. Turnover Rating
CIBC Energy Fund
3.0M
$385,778 +3% 1.5%
Sector Specific
CIBC Canadian ...
1.6M
$197,365 +1% 0.8%
Specialty
Sprott Canadian ...
365.8K
$46,472 0% 0.2%
GARP
Bullboard Posts